Supreme Court focuses on ‘pay for delay’ deals

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

WASHINGTON—”Pay for delay” deals between big pharmaceutical companies and generic drug competitors are going before the United States Supreme Court.

Federal regulators are pressing the high court to stop big pharmaceutical companies from paying generic drug competitors to delay their releases of cheaper versions of brand name drugs.

The Obama Administration says the so-called “pay for delay” deals profit the drug companies while harming consumers by denying them price declines.

Instead, the deals add $3.5 billion each year to Americans’ drug bills.

Latest News

More News

National News

More National

Washington D.C.

More Washington

Your Local Election HQ

More Your Local Election HQ

Contact In Your Corner Team

Don't Miss

Latest News

More News

KFOR Digital Originals

More Digital Original


Follow @KFOR on Twitter